Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DSP107 + azacitidine
- Development stage
- Discontinued
- Lead developer
- KAHR Medical
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Subcutaneous, Oral
01
Overview
DSP107 + azacitidine is a combination regimen of a first-in-class bispecific fusion protein (DSP107) and the hypomethylating agent azacitidine. DSP107 is designed to simultaneously block the CD47/SIRPα "don't eat me" signal on tumor cells, which inhibits phagocytosis, and activate the 4-1BB costimulatory receptor on T cells, thereby enhancing both innate (macrophages, neutrophils) and adaptive (T cells) antitumor immunity in the tumor microenvironment. Azacitidine is a pyrimidine nucleoside analogue that incorporates into DNA and RNA, disrupting nucleic acid metabolism and inhibiting DNA methyltransferase, leading to hypomethylation and apoptosis of malignant hematopoietic cells. Both agents are investigated in combination for hematologic malignancies, such as myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), aiming to synergistically promote antitumor immune responses and epigenetic modulation[2][3][5].
- Brand names
- Azacitidine AccordAzacitidine BetapharmAzacitidine KabiAzacitidine Mylan
- Other names
- DSP 107DSP107DSP-107KAHR-107KAHR107KAHR 107
02
Targets
CD47 (Cluster of Differentiation 47)DNMT (DNA methyltransferase)SIRPA (Signal-regulatory protein alpha)TNFRSF9 (CD137 extracellular domain)DNA
Beyond the preview
Go deeper on DSP107 + azacitidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DSP107 + azacitidine.